{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-047158","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2026-10-15T12:45:26+00:00","discovered_at":"2026-10-15T12:50:00.337109+00:00","generated_at":"2026-10-15T12:50:17.525608+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Vivos Therapeutics to issue $12M Series C preferred for 11% SOD Sciences stake and 50% test co-ownership","bullets":["Vivos will issue 12,000 Series C Convertible Preferred shares with $1,000 stated value each, totaling $12 million, to SOD Sciences.","Consideration includes 2,907,338 SOD common shares, at least 11% fully diluted, and a 50% undivided interest in SOD's pseudohypoxia test IP.","Series C preferred is convertible at fixed $0.15 per share into up to 80 million common shares, subject to a 19.99% exchange cap.","Nasdaq minimum $2.5 million stockholders' equity compliance: pro forma equity of about $8 million exceeds requirement by $5.5 million after the deal.","Closing expected October 15, 2026, subject to independent valuation, auditor concurrence, Streeterville Capital consent, Nasdaq notification, and SOD consents."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-047158","json":"https://secwatch.observer/filing/0001493152-26-047158.json","markdown":"https://secwatch.observer/filing/0001493152-26-047158.md","text":"https://secwatch.observer/filing/0001493152-26-047158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/0001493152-26-047158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/form8-k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-15T12:50:17.525608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}